1,769 results on '"Wu, Y.-L."'
Search Results
202. 658MO Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors
203. Prediction of the planet yield of the MaxProtoPlanetS high-contrast survey for H-alpha protoplanets with MagAO-X based on first light contrasts
204. Early noninvasive cardiac testing after emergency department evaluation for suspected acute coronary syndrome
205. A Salmonella Infection Complicated With Suppurative Thyroiditis and Ruptured Aortic Mycotic Aneurysm in a Renal Transplant Recipient
206. Rapid screening of Musa species for resistance to Fusarium wilt in an in vitro bioassay
207. Epigenetic plasticity of hTERT gene promoter determines retinoid capacity to repress telomerase in maturation-resistant acute promyelocytic leukemia cells
208. Synthesis and crystal structure of complex [Mn(Imdc)2(H2O)2] · 2H2O and its interaction with DNA
209. Safety profile of afatinib in first-line therapy of patients with metastatic EGFR mutation-positive (M+) non-small cell lung cancer (NSCLC): Comparative analysis of Asian and non-Asian patients from two randomized trials: ID 242
210. Molecular basis of complete complement C4 deficiency in two North-African families with systemic lupus erythematosus
211. 32O First-in-human (FIH) study of SCC244, a novel potent and highly selective c- MET inhibitor, in patients (pts) with advanced non-small cell lung cancer (NSCLC)
212. Hypoxia-inducible factor-1α-induced differentiation of myeloid leukemic cells is its transcriptional activity independent
213. P3.12D.06 Beamion LUNG-1 And LUNG-2: The Zongertinib Clinical Program in Patients with Non-Small Cell Lung Cancer and HER2 Mutations
214. P3.08F.02 MRD Guiding Treatment after Aumolertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model (APPROACH)
215. Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
216. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cδ
217. Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial
218. Large strong phases and CP violation in the annihilation processes B̄0→K+K-, K*±K∓, K*+K*-
219. Cavitation resonance: The phenomenon and unknown
220. Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women
221. POTENTIAL MECHANISMS OF RESISTANCE IDENTIFIED THROUGH ANALYSIS OF MULTIPLE BIOMARKERS IN IMMUNE HOT NON-RESPONDERS WITH NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH TISLELIZUMAB
222. MO01.48 INSIGHT 2: Tepotinib + Osimertinib in EGFR-Mutant NSCLC with Resistance to 1st-Line Osimertinib due to MET Amplification
223. TS01.03 Efficacy and Safety Data From a Phase 1/2 Trial of Tislelizumab in Chinese Patients With Non-Small Cell Lung Cancer (NSCLC)
224. Comparison of the Clinical Efficacy of Proximal Femoral Nail Antirotation and Femoral Head Replacement on Intertrochanteric Fracture and the Influence of Tartrate Resistant Acid Phosphatase 5b and Bone Alkaline Phosphatase
225. Toxic Effects of Aminophenols on Aquatic Life Using the Zebrafish Embryo Test and the Comet Assay
226. CP asymmetry in $B \rightarrow \phi K_{S}$ in a general two-Higgs-doublet model with fourth-generation quarks
227. 359P The role of adjuvant targeted therapy for postoperative EGFR mutant non-small cell lung cancer: A network meta-analysis
228. 389P Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
229. 360P Number of lymph nodes examined was not an independent risk factor for the survival of patients with stage IA1-2 lung adenocarcinoma undergoing sublobar resection
230. 383MO Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping
231. 363P Genetic predisposition for pre-invasive lung adenocarcinoma manifesting as ground-glass nodules with family history of lung cancer
232. 356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence
233. 357P Comparison between immunotherapy and chemotherapy as neoadjuvant setting in resectable non-small cell lung cancer: A systematic review and meta-analysis of prospective trials
234. 161O RESILIENT part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer (SCLC)
235. 42P Pembrolizumab vs chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC) and PD-L1 TPS ≥1%: 5-year update from KEYNOTE-042
236. 40P Updated data from the phase I Beamion Lung 1 trial of BI 1810631, a HER2 TKI, in patients (pts) with advanced solid tumours with HER2 aberrations
237. A meshfree formulation of local radial point interpolation method (LRPIM) for incompressible flow simulation
238. Lepton flavor-changing scalar interactions and g-2 of the muon
239. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
240. Reply to ‘Concern on quality-of-life analysis in the OPTIMAL study’ by Couraud et al
241. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
242. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)†
243. Development of RBF-DQ method for derivative approximation and its application to simulate natural convection in concentric annuli
244. The HLA-B gene and Hashimoto disease in Han Chinese children: a case-control and family-based study
245. Searching for rephase-invariant CP- and CPT-violating observables in meson decays
246. CP violation, fermion masses and mixings in a predictive SUSY SO(10) × Δ(48) × U(1) model with small tanβ
247. The HLA-DRB1 gene and Graves disease in Taiwanese children: a case-control and family-based study
248. Prognostic significance of cyclinD1 amplification and the co-alteration of cyclinD1/pRb/ppRb in patients with esophageal squamous cell carcinoma
249. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
250. COMBINATIONS OF LAMININ 5 WITH PTEN, P-EGFR, AND P-AKT DEFINE A GROUP WITH POORER PROGNOSIS IN PATIENTS WITH NSCLC
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.